Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive individuals receiving highly active antiretroviral therapy | Zendy

Alan Winston | Zendy; Mark Bloch | Zendy; Andrew Carr | Zendy; Janaki Amin | Zendy; Patrick Mallon | Zendy; John E. Ray | Zendy; Debbie Marriott | Zendy; David A. Cooper | Zendy; Sean Emery | Zendy

Open Access

Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive individuals receiving highly active antiretroviral therapy

Author(s) -

Alan Winston,

Mark Bloch,

Andrew Carr,

Janaki Amin,

Patrick Mallon,

John E. Ray,

Debbie Marriott,

David A. Cooper,

Sean Emery

Publication year - 2005

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dki235

Subject(s) - atazanavir , ritonavir , dosing , medicine , trough concentration , lopinavir , concomitant , pharmacology , nevirapine , therapeutic drug monitoring , pharmacokinetics , viral load , virology , human immunodeficiency virus (hiv) , antiretroviral therapy

Atazanavir is a recently approved HIV protease inhibitor (PI). As with other PIs, careful attention to potential pharmacokinetic drug interactions in clinical practice is necessary. The aim of this study was to assess the clinical associations with plasma atazanavir concentrations in HIV-positive individuals.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research